Visualizing the brutal drops in today's biggest stock losers.
By GLHR Investing Staff November 9, 2025
In a turbulent trading session on Wall Street, several stocks suffered brutal beatings as broader market jitters over economic data and corporate earnings reports sent shares spiraling. The S&P 500 dipped amid concerns about slowing growth, but these 10 names took the hardest hits, with some plunging more than 70%. From disappointing trial results to revenue shortfalls, here’s a breakdown of the biggest losers and the forces fueling their freefalls.
| Rank | Ticker | Closing Price | Change % | Key Reason |
|---|---|---|---|---|
| 1 | DTCK | $1.41 | -77.93% | Sharp reversal after a multi-day surge of over 150%, likely triggered by profit-taking and heightened volatility in small-cap commodities plays. |
| 2 | ENGS | $1.80 | -53.79% | Weaker-than-expected earnings and a delayed filing eroded investor confidence in this capital goods firm, accelerating annual losses to 14.1%. |
| 3 | ELDN | $2.06 | -49.76% | Clinical trial results disappointed, sending biotech shares tumbling over 50% as financial struggles and analyst downgrades piled on the pressure. |
| 4 | OPPr | $0.0056 | -44.00% | Amid a wave of small-cap volatility, this obscure name saw outsized selling with no major news, reflecting broader risk-off sentiment in penny stocks. |
| 5 | AFJK | $12.50 | -42.06% | Trading halt due to extreme volatility followed an extension of its business combination deadline, spooking investors after an earlier merger-fueled rally. |
| 6 | AIRS | $6.12 | -41.85% | Q3 revenue plunged, prompting a slashed guidance that wiped out nearly half the stock’s value in a single day of heavy selling. |
| 7 | RFL.WS | $0.0338 | -39.80% | Warrants nearing expiration in December, combined with revised subscription rights in a rights offering, amplified downside pressure on this derivative. |
| 8 | MEHA | $0.6899 | -39.23% | Fresh off a Nasdaq direct listing last week, post-IPO selling and debut jitters contributed to a steep drop in this consumer health newcomer. |
| 9 | BZFD | $1.06 | -34.66% | Q3 revenue miss and lowered 2025 guidance to $185M-$195M, hit by ad softness and affiliate bonus declines, crushed digital media hopes. |
| 10 | MSGY | $0.95 | -34.04% | Volatility trading halt overshadowed this wet-trades subcontractor’s operations, amid a weekly market slide across major indices. |
These declines underscore the fragility in certain sectors like biotech, digital media, and small-caps, where bad news travels fast. Investors are eyeing upcoming jobs data and Fed signals for clues on whether this is a blip or the start of something bigger. Stay tuned to GLHR Investing for real-time updates as markets evolve.
